SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.
(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

RENOUNCEABLE NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE

- LISTING AND QUOTATION OF RIGHTS SHARES AND WARRANTS

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below) and the Offer Information Statement (as defined below).

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**", together with its subsidiaries, collectively, the "**Group**") refers to the Company's announcements dated 30 October 2025, 13 February 2026, 22 April 2026, 12 May 2026, 20 May 2026, 2 June 2026, 4 June 2026 and 23 June 2026 (collectively, the "**Announcements**"), and the Offer Information Statement dated 2 June 2026 ("**Offer Information Statement**") in relation to, *inter alia*, the renounceable non-underwritten Rights cum Warrants Issue to be undertaken by the Company.

The Board wishes to announce that the 492,597,856 Rights Shares and 492,597,856 Warrants have respectively been allotted and issued on 24 June 2026, pursuant to the Rights cum Warrants Issue.

Following the allotment and issuance of 492,597,856 Rights Shares, the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) has increased from 1,231,494,642 Shares to 1,724,092,498 Shares.

The 492,597,856 Rights Shares are expected to be listed and quoted on the Catalist with effect from 9.00 a.m. on 26 June 2026, and trading of the Rights Shares is expected to commence with effect from 9.00 a.m. on the same date.

The 492,597,856 Warrants are expected to be listed and quoted on the Catalist with effect from 9.00 a.m. on 29 June 2026, and trading of the Warrants is expected to commence with effect from 9.00 a.m. on the same date.

The Warrants may be exercised during the period commencing on and including the date of issue of the Warrants and expiring at 5.00 p.m. on the date immediately preceding the expiry of 60 months from the date of issue of the Warrants (unless such date is a date on which the register of members and/or register of warrantholders is/are closed or is not a Business Day (as defined in the Deed Poll), in which event the Warrants shall expire on the immediately preceding Business Day), but excluding such period(s) during which the register of warrantholders may be closed pursuant to the Deed Poll, subject to the terms and conditions of the Warrants as set out in the Deed Poll.

The Warrant Shares arising from the exercise of the Warrants will, upon allotment and issue, be listed and quoted on the Catalist.

The Warrant Shares arising from the exercise of the Warrants will, upon allotment and issue, rank *pari passu* in all respects with the then existing issued Shares for any dividends, rights, allotments or other distributions, the record date for which falls on or after the date of issue of the Warrant Shares, save as may be otherwise provided in the Deed Poll.

The listing and quotation notice granted by the SGX-ST on 11 May 2026 for the dealing in and the listing of and quotation for (i) up to 492,597,856 Rights Shares to be issued by the Company, (ii) up to 492,597,856 Warrants to be issued by the Company, and (iii) up to 492,597,856 Warrant Shares to be issued by the Company upon the exercise of the Warrants, pursuant to the Rights cum Warrants Issue, on the Catalist of the SGX-ST, is not to be taken as an indication of the merits of the Rights cum Warrants Issue, the Rights Shares, the Warrants, the Warrant Shares, the Company, its subsidiaries and their securities.

Further update announcement(s) on the Warrants will be made by the Company as and when appropriate.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
24 June 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.